# 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

> **NCT02008916** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 226 (actual)

## Conditions studied

- Spondylitis, Ankylosing

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Placebo secukinumab

## Key facts

- **NCT ID:** NCT02008916
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-14
- **Primary completion:** 2015-02-23
- **Final completion:** 2017-12-11
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2019-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02008916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02008916, "16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02008916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*